A gossypiboma masquerading as a mesenteric cyst

Gossypiboma refers to foreign bodies left inside the body during surgery, such as sponges and gauze. These foreign bodies represent a significant cause of morbidity and mortality.A 57-year-old female presented to us with right upper abdominal pain. Her past history was non-contributory except for an open cholecystectomy 20 years previously. A physical examination revealed tenderness to palpation on the right of the abdomen, while the remaining examination was normal. An abdominal computed tomography (CT) and magnetic resonance imaging (MRI) scan revealed a well-defined calcified mass of 5 cm that was compatible with a mesenteric cyst. During surgery, the mass was found to be adherent to the mesocolon and to have invaded the colon wall. A right hemicolectomy and ileotransverse anastomosis was performed. The pathological mass was considered to be a gossypiboma that had been left behind during the earlier cholecystectomy. The body’s reaction to the foreign body was seen to extend beyond the lamina propria and muscularis propria. Gossypiboma is an undesired and life-threatening but preventable surgical complication. This condition may present with nonspecific findings and a clinical scenario that mimics various disorders, even after many years. A diagnosis of gossypiboma should be kept in mind for patients with a history of previous operations and undergoing surgery due to the suspicion of a mesenteric cyst

Evaluation of Subfoveal Choroidal Thickness in Internal Carotid Artery Stenosis

Purpose. To evaluate the relationship between internal carotid artery (ICA) stenosis and subfoveal choroidal thickness (SFCT) in the elderly population. Methods. A total of 42 eyes of 21 patients with more than 70% ICA stenosis (Group 1) on one side and less than 70% stenosis (Group 2) on the other side were recruited for this study. ICA stenosis was diagnosed using both the B-mode and Doppler ultrasound. The two groups were compared in terms of the percentage of stenosis, SFCT measurements, intraocular pressure, ocular perfusion pressure, refractive error, and peak systolic velocity. Eyes were examined with the RTVue-100 OCT device by the EDI-OCT technique. Results. The mean age of the patients was 71.9±10.8 years. The mean percentage of ICA stenosis was 74±4.9% in Group 1 and 47.5±7.7% in Group 2. The mean SFCT was 231.9±44.6 μm in Group 1 and 216.2±46.8 μm in Group 2, which was significantly lower (P=0.028). A statistically significant positive correlation was found between the percentage of internal carotid artery stenosis and SFCT (r=0896, P=0.001). Conclusions. Compensatory SFCT increase can be seen in ipsilateral internal carotid artery stenosis greater than 70%

Ipsilateral Rotational Autokeratoplasty for the Management of Traumatic Corneal Scar

A 40-years-old male patient with a corneal scar secondary to perforating eye injury had undergone ipsilateral rotational autokeratoplasty in our clinics. The corneal scar involved the pupillary area. The patient had a preoperative visual acuity of counting fingers. The patient’s cornea was trephined with a 0.5 mm temporal decentration. The 8.0 mm autograft was rotated approximately 180° to relocate the scar to the temporal aspect of the cornea. The final position of the corneal scar was temporal of the visual axis and central area was clear. The visual acuity at 1-, 3-, and 6-months followups was better than the first visual acuity in the patient. Ipsilateral rotational autokeratoplasty has many advantages over conventional keratoplasty. There is no risk of immunological rejection of the graft, postoperative corticosteroids are not needed as frequently, and donor cornea is not required. A rotational autograft can be a powerful alternative to conventional keratoplasty for some patients with traumatic corneal scars

Past, present, and future of therapies for pituitary neuroendocrine tumors: need for omics and drug repositioning guidance

Innovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs\" treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy

Living with Burden of igraine: The Analysis of "my migraine Voice" Survey Results in Turkey

Introduction: Migraine is a common, chronic neurologic disease which causes serious social and economical disability at both the individual and the community level. The aim of this study was to interpret the data for Turkey from "My Migraine Voice," an online survey of individuals suffering from frequent migraine attacks (>= 4 days/month with migraine headaches) who had not benefited from existing prophylactic therapies, conducted in 31 countries to investigate the burden of migraine for the individual and the society

Ankara'da 1980'li ve 90'lı yıllarda gelişen Rock müzik ve bu akım çevresinde A-Bar

Ankara : İhsan Doğramacı Bilkent Üniversitesi İktisadi, İdari ve Sosyal Bilimler Fakültesi, Tarih Bölümü, 2013.This work is a student project of the The Department of History, Faculty of Economics, Administrative and Social Sciences, İhsan Doğramacı Bilkent University.by Elif Huntürk.Huntürk, Elif. HIST 200-8HUNTÜRK HIST 200-8/4 2012-1

Metastatik küçük hücre dışı akciğer kanserinde taxan-sisplatin mombinasyonu ile gemsitabin-sisplatin kombinasyonunun karşılaştırılması

In the first stage treatment of NSCLC, it is controversial which treatment combination should be preferred and advantage of one combination over the other could not be shown. The purpose of this study is to compare gemcitabine-cisplatin combination and taxan-cisplatin combination in phase 4 NSCLC with, in terms of efficacy, cost and toxicity. Patients whose diagnoses were phase 4 NSCLC in, Department of Medical Oncology between 2008-2011 have been collected. All diagnosis were confirmed histopathologically and radiologically shown to be metastatic. When two regimens were evaluated together, median survival of the patients was determined as 10,6 (95% confidence interval 5,4- 15,7) months. While survivel time was 8,1 months ( %95 confidence interval 5,1- 11,27 ) for Gemzar-cisplatin regimen, it was 14 months (95% confidence interval 5,5- 22,5) in taxan-cisplatin regimen. But when the difference between survival times was evaluated with long rank test, statistically significant difference was not determined. We argue that, while choosing the combination thrapy in the first stage therapy of phase 4 NSCLC, besides the performance status of the patient and possible side effects, cost of the therapy should also be taken into consideration.Metastatik küÇük hücre dışı akciğer kanserinde birinci basamak tedavide hangi tedavi kombinasyonunun tercih edilmesi gerektiği tartışmalıdır. Bu Çalışmamızın amacı evre 4 KHDAK’de sık kullandığımız gemsitabin-cisplatin kombinasyonuna karşı taxan-sisplatin kombinasyonunun etkinlik toksite ve maliyetini karşılaştırmaktır. 2008-2011 yılları arasında Tıbbi Onkoloji kliniğinde histopatolojik olarak tanısı doğrulanmış ve görüntüleme yöntemleri ile metastatik olduğu gösterilmiş hastalar Çalışmaya alınmıştır. Her iki tedavi rejimi birlikte değerlendirildiğinde hastaların medyan yaşam süresi 10,6 (%95 güven aralığı 5,4- 15,7 ) ay olarak tespit edildi. Gemzar-sisplatin kolunda bu süre 8,1 ( %95 güven aralığı 5,1- 11,27 ) ay iken taksan-sisplatin kolunda 14 (%95 güven aralığı 5,5- 22,5 ) ay olarak tespit edildi. Yaşam süreleri arasındaki fark long rank testi ile değerlendirildiğinde istatiksel anlamlı fark tespit edilmedi. Evre 4 KHDAK ilk basamak tedavisinde kombinasyon seÇiminde hastanın performans durumu, olası tedavi etkileri yanında tedavi maliyetinin de göz önünde bulundurulması gerektiğini düşünüyoruz